Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Colorcon
Moodys
Express Scripts
Mallinckrodt
Covington
Farmers Insurance
Dow
Julphar
AstraZeneca

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 075731

« Back to Dashboard

NDA 075731 describes CLORAZEPATE DIPOTASSIUM, which is a drug marketed by Able, Am Therap, Aurolife Pharma Llc, Dava Pharms Inc, Gd Searle Llc, Mylan, Purepac Pharm, Quantum Pharmics, Usl Pharma, Warner Chilcott, Watson Labs, Lederle, Sun Pharm Inds Ltd, and Taro Pharm, and is included in fifty-eight NDAs. It is available from eight suppliers. Additional details are available on the CLORAZEPATE DIPOTASSIUM profile page.

The generic ingredient in CLORAZEPATE DIPOTASSIUM is clorazepate dipotassium. There are eight drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.
Summary for 075731
Tradename:CLORAZEPATE DIPOTASSIUM
Applicant:Taro Pharm
Ingredient:clorazepate dipotassium
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 075731
Ingredient-typeBenzodiazepines
Medical Subject Heading (MeSH) Categories for 075731
Suppliers and Packaging for NDA: 075731
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 075731 ANDA Rebel Distributors Corp 21695-433 E 21695-433-60
CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 075731 ANDA Rebel Distributors Corp 21695-434 E 21695-434-60

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength15MG
Approval Date:Apr 27, 2000TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength7.5MG
Approval Date:Apr 27, 2000TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength3.75MG
Approval Date:Apr 27, 2000TE:ABRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Moodys
Harvard Business School
Healthtrust
Mallinckrodt
US Department of Justice
Fish and Richardson
Daiichi Sankyo
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot